Lilly joins Series A backing a platform designed to turn adipocytes into long-term, adjustable producers of therapeutic proteins.
Remedium Bio has announced the initial close of a planned $10 million Series A financing, bringing new capital to its effort to develop durable, adjustable gene therapies for chronic disease. The round is led by Lifespan Vision Ventures, with participation from Eli Lilly and Company and HKX Capital; Harry Robb of Lifespan Vision Ventures has joined Remedium’s board. The company says it expects to complete the round with a further group of investors before final close.
The Boston biotech’s Prometheus platform is designed to use adipocytes – fat cells – at the site of a minimally invasive subcutaneous injection as long-term producers of therapeutic proteins. Rather than repeatedly administering the protein itself, Remedium aims to provide the genetic instructions for the patient’s own cells to manufacture it, potentially for years; importantly, the company says expression can subsequently be adjusted according to therapeutic need. The financing will support its lead programs and preparations for first-in-human studies.
Longevity.Technology: Durability has always been both gene therapy’s promise and its problem. A treatment capable of producing therapeutic benefit for years has obvious appeal for chronic conditions currently managed through repeated injections; permanence becomes rather less attractive, however, when biology changes, therapeutic requirements shift or the original dose turns out not to have been quite as clever as everyone hoped. Remedium’s proposition attempts to loosen that particular knot: its platform is designed to turn adipocytes into durable producers of therapeutic proteins while retaining the ability to adjust expression after treatment. In effect, the body becomes an endogenous drug factory – but, crucially, one that is intended to come with a dial.
That distinction between durable and fixed could prove important as gene therapy increasingly blurs into drug delivery rather than simply gene replacement. But adjustability is also the claim on which much of the platform’s promise rests; expression must be predictable, controllable and safe over potentially long periods – three requirements considerably easier to assemble in a sentence than in a patient. Remedium remains preclinical, and its Series A is financing the journey towards first-in-human development; demonstrating that long-lived genetic programming need not mean surrendering control of the dose will be the considerably more interesting milestone.
Fat gets another job
Adipose tissue is perhaps an unconventional choice of pharmaceutical factory only if one thinks of fat as passive storage. Adipocytes are metabolically and endocrinologically active cells, participating in systemic signaling; Remedium’s approach seeks to co-opt that biology locally, turning cells at the injection site into producers of a chosen therapeutic protein while limiting systemic vector exposure.
That localization is important to the company’s ambition to move gene therapy beyond the rare diseases with which the modality has traditionally been associated. Systemic vector administration can create challenges around tissue tropism, toxicity and dosing, while immune responses can make redosing difficult; an inability to titrate expression once a therapy has been given is a particularly awkward constraint when treating common chronic conditions.
“Our leverage comes in part from localizing treatment to adipocytes at the injection site and administering it through a minimally invasive subcutaneous injection,” CEO and cofounder Frank Luppino told Longevity.Technology. “This is designed to reduce systemic exposure while using an accessible and well-characterized tissue to produce the intended therapeutic protein.”
A fat cell with a second career, then – although the clinical data will have to establish how reliably it performs the new job.
A very long dosing interval
The healthspan proposition becomes clearer when viewed against the rise of chronic protein and peptide medicines, particularly in cardiometabolic disease. Highly effective therapies are of limited use when patients cannot or do not remain on them; regular administration also creates peaks and troughs in exposure, logistical burden and accumulating healthcare costs.
“The shift would be fundamental,” Luppino said of converting chronic protein delivery into a single, multi-year intervention. “Today, even highly effective preventive medicines depend on patients taking them week after week, often for decades.”
Remedium expects cardiometabolic disease – particularly obesity and type 2 diabetes – to provide an early opportunity. Both conditions can emerge relatively early in the trajectory of age-related multimorbidity and increase subsequent risks across cardiovascular, renal and functional health.
“Improving metabolic health earlier and more consistently could therefore deliver benefits across multiple dimensions of healthspan,” said Luppino, adding that cardiometabolic health represents “the first and most immediate opportunity – not the limit of the platform.”
The price of permanence
There is an economic wrinkle here too. Gene therapies have largely developed around small patient populations and correspondingly substantial price tags; protein biologics aimed at common chronic diseases operate at an altogether different scale.
Remedium argues that localized administration and adjustable expression could broaden the range of conditions amenable to gene-based treatment, while larger target populations could spread development and manufacturing costs across markets unavailable to orphan-focused therapies.
That is still a hypothesis rather than a health-economic outcome. Yet it points towards an interesting inversion: instead of gene therapy being reserved for conditions sufficiently rare and severe to justify extraordinary upfront expenditure, the technology might eventually compete with medicines whose individual doses are less expensive but whose costs accumulate over decades.
“By overcoming these technical constraints and designing therapies for large patient populations, we can pursue a different economic model,” Luppino told us. “Manufacturing and development costs can be distributed across larger markets, creating economies of scale that have historically been unavailable to orphan-focused gene therapies.”
For investors, that combination of platform breadth and chronic-disease scale is evidently part of the attraction. Remedium says the Series A will also support expansion of its platform technologies and pipeline, which spans endocrinology, immunology, neurology and musculoskeletal disease. “We look forward to completing the round with a select group of additional investors who share our vision for transforming the delivery of chronic protein therapies,” Luppino said.
“Remedium has developed a differentiated platform with the potential to address significant limitations of chronic biologic treatment,” said Andrew Worden of Lifespan Vision Ventures. “We are pleased to lead the Series A and support the company as it advances its pipeline, moves toward clinical development, and expands the breadth of its platform.”
When the dial meets the clinic
The next test is necessarily less elegant than the platform diagram. Human biology will determine whether expression can be maintained at therapeutically useful levels and adjusted with sufficient precision over time – and whether doing so retains an acceptable safety profile.
With Series A proceeds earmarked partly for first-in-human preparation, Remedium is approaching the point where those questions begin moving from engineering proposition to clinical evidence. As Luppino puts it, adjustable expression is intended to give physicians “a practical way to respond to changes in an individual patient’s therapeutic needs over time.”
For a medicine intended to last years, the ability to change one’s mind may prove almost as important as the ability to make it last.
